



August 19, 2019

BY ELECTRONIC DELIVERY

Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Celgene is providing notice of the introduction of a new prescription drug with a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program:

- INREBIC[®] (fedratinib) [59572-0720-12]

Sincerely,

A handwritten signature in blue ink that reads "James Kilgallon".

James Kilgallon
Executive Director, Pricing and Contracting Strategy